VIR - Vir Biotechnology Inc. (VIR) Q4 2023 Earnings Call Transcript

2024-02-22 20:48:06 ET

Vir Biotechnology, Inc. (VIR)

Q4 2023 Results Conference Call

February 22, 2024 04:30 PM ET

Company Participants

Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer

Marianne De Backer - Chief Executive Officer

Phil Pang - Chief Medical Officer

Sung Lee - Chief Financial Officer

Conference Call Participants

Nik Gasic - Leerink Partners

Eva Privitera - TD Cowen

Patrick Trucchio - H.C. Wainwright

Eric Joseph - JP Morgan

Alec Stranahan - Bank of America

Joseph Stringer - Needham & Company

Michaels Ulz - Morgan Stanley

Presentation

Operator

Hello. Welcome to Vir Biotechnology’s Fourth Quarter and Full Year 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen only mode. After the speakers’ presentation, there will be a question and answer session.

I will now turn the call over to Sasha Damouni Ellis, Executive Vice President, Chief Corporate Affairs Officer. You may begin, Ms. Damouni Ellis.

Sasha Damouni Ellis

Thank you, and good afternoon. With me today are Dr. Marianne De Backer, Chief Executive Officer; Dr. Phil Pang, Chief Medical Officer; and Sung Lee, Chief Financial Officer. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements, to differ significantly from those expressed or implied by such forward looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including forms 10-K, 10-Q and 8-K. I will now turn the call over to our CEO, Marianne De Backer....

For further details see: